• Wellness
• Safety and quality
• Policy

What a USP monograph actually is (and why peptide policy keeps bumping into it)

By Peptide Policy Watch staff · Published November 6, 2026 · 5 min read · 6 sources, 6 checked at the source

When a standards body says a peptide "has no monograph," it isn't calling the substance fake. It's pointing at a missing public quality document. The U.S. Pharmacopeia's own overview page spells out what those documents are for — identity, strength, purity, performance — and what they are not. Understanding that vocabulary makes the November 3, 2026 USP statement on HHS's six-peptide policy a lot less mysterious.

Facts are as of November 6, 2026. Sources, with retrieval dates, are at the bottom.

Three kinds of USP–NF standards

USP's public overview of monographs describes the United States Pharmacopeia–National Formulary as holding more than 5,000 quality standards for medicines (chemical and biologic), active pharmaceutical ingredients and excipients. [V] For prescription medicines it groups those standards into three types:

1. Monographs — written quality expectations for a medicine, including identity, strength, purity and performance, and the tests that show whether a medicine and its ingredients meet those criteria. [V]
2. General chapters — broader process, test and method information that supports development and manufacturing. [V]
3. Reference standards — physical materials used with monographs and general chapters to check that a medicine or ingredient can pass the tests. [V]

USP describes itself as the official U.S. quality compendium for marketed medicines, with use in more than 140 countries. [V]

What a monograph is checking

On USP's telling, a monograph reflects quality attributes of medicines FDA has approved. [V] The overview breaks those attributes into four everyday words:

• Identity — tests that the substance is what the label claims. [V]
• Strength — methods and acceptable ranges for potency, as reflected in FDA's approvals. [V]
• Purity — which impurities may be present, how much is allowed, and how to measure them. [V]
• Performance — lab tests meant to predict how a medicine releases as it enters the body. [V]

That list is about quality documentation. It is not a consumer shopping checklist, and it is not a how-to for vetting any seller. [V]

USP puts the boundary in plain language: approval, biosimilarity and interchangeability are FDA's call. [V]

How a monograph gets written

USP says the writing usually begins several years ahead of an originator product's patent cliff, often with the license holder working with a USP Expert Committee. [V] Those committees draw on unpaid scientific volunteers from academia, industry and practice; FDA experts sit in as government liaisons. [V] A monograph typically becomes public after patent protection expires and after a transparent comment process. [V]

Monographs also get revised when FDA approves products with different quality specifications, when FDA or others bring new safety-related data, or when testing technology moves. [V] USP's Pending Monograph Program is a path for updating a monograph quickly around the time of FDA approval. [V]

Why this showed up in the six-peptide fight

On November 3, 2026, USP published a statement on HHS's enforcement-discretion policy for certain peptide bulk substances under section 503A. [V] USP said it is concerned about potential harm from unapproved peptide products, and that the HHS policy "does not include essential safeguards" for quality and safety of compounded preparations built from those bulk substances. [V]

The concrete gap USP named: those peptide bulks lack USP–NF monographs, lack USP Reference Standards, and lack established substance names (USAN, INN or IUPAC examples) that pin down identity and quality attributes. [V] USP said its scientific review before the July 2026 Pharmacy Compounding Advisory Committee meeting found those substances "not sufficiently characterized" for consistent quality evaluation. [V] It also said the USP standards the policy cites are not enough by themselves for quality assurance, because they do not set the substance- and product-specific specs you get when each bulk is tied to a monograph plus a matching reference material. [V]

And USP closed the loop the same way its monograph overview does: standards work does not take over a regulator's job of judging safety and effectiveness. [V]

Our USP / HHS policy brief covers that statement in the comment-period context. Our cGMP and certificate-of-analysis explainer is the neighboring vocabulary page for manufacturing and lab paperwork. Comments on docket HHS-OASH-2026-0496 close at 11:59 PM Eastern on November 13, 2026. [V]

What a monograph is not

It is not a green light that a product works for you. [V] It is not proof of biosimilarity or interchangeability. [V] It is not permission to market a medicine. [V] It is not a vendor-verification manual, and this page is not instructions for shopping or for checking any particular seller. [V]

Quality standards and regulatory approval answer different questions. When peptide policy arguments lean on "monograph" language, the useful move is to ask which document exists, what it covers, and which agency still owns safety and effectiveness. For the six peptides named in the HHS policy, USP's November 3 answer was that the monograph and reference-standard pieces are missing. [V]

Sources (retrieved November 6, 2026)

1. U.S. Pharmacopeia, "An Overview of USP Monographs" [V] — https://www.usp.org/about/public-policy/overview-of-monographs
2. U.S. Pharmacopeia, "USP statement on quality and safety considerations for unapproved peptides," November 3, 2026 [V] — https://www.usp.org/news/usp-statement-on-quality-and-safety-considerations-for-unapproved-peptides
3. Peptide Policy Watch, USP statement brief on the HHS six-peptide policy [V] — https://peptidepolicywatch.com/2026/11/04/usp-hhs-peptide-policy-quality-safeguards-monographs/
4. Peptide Policy Watch, cGMP and certificate of analysis (concepts) [V] — https://peptidepolicywatch.com/2026/11/01/cgmp-certificate-of-analysis-peptides-what-they-mean/
5. Regulations.gov, docket HHS-OASH-2026-0496 (comment end 11:59 PM Eastern November 13, 2026) [V] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
6. Federal Register, HHS enforcement-discretion policy notice, 91 FR 68526, document 2026-22192, October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits